Efficacy and Safety of Methoxy Polyethylene Glycol Epoetin - Beta versus Epoetin Alpha for Treatment of Chronic Renal Anemia in Hemodialysis Patients

Abeer K. Jumaa^1, , Hassan M. Abbas Al Temimi², May S. Alsabbagh¹ and Jawad I.Rasheed³

¹Clinical Pharmacy Department, College of Pharmacy/ Baghdad University, Baghdad, Iraq

²Clinical Pharmacy Department, Medical city, Baghdad, Iraq

³Nephrology Department, Medical city, Baghdad, Iraq

Cite this paper:
Abeer K. Jumaa, Hassan M. Abbas Al Temimi, May S. Alsabbagh and Jawad I.Rasheed. Efficacy and Safety of Methoxy Polyethylene Glycol Epoetin - Beta versus Epoetin Alpha for Treatment of Chronic Renal Anemia in Hemodialysis Patients. American Journal of Pharmacological Sciences. 2015; 3(4):87-93. doi: 10.12691/ajps-3-4-1

Abstract

Objective: Chronic kidney disease is a common health problem in the world and anemia is of its common complication. The aim of this study was to evaluate the efficacy and the safety of methoxy polyethylene glycol-epoetin beta in comparison with epoetin alfa in treating chronic renal anemia in hemodialysis patients. Methods: A single center randomized controlled open labeled clinical trial with three months duration was performed. 46 Patients with chronic renal anemia were allocated randomly to receive either methoxy polyethylene glycol-epoetin beta (100μg) every two week or epoetin alfa (4000 IU) twice weekly and were evaluated at baseline and monthly after starting their treatments for 3 months. Clinical assessment was done by measuring hemoglobin concentration, packed cell volume, reticulocyte count, iron parameter, potassium level, platelets count and monitoring of the adverse events. Results There was a statistically significant increase in haemoglobin concentration, packed cell volume, and reticulocyte count in the both groups. The rise in haematological parameters in methoxy polyethylene glycol-epoetin beta group was non significantly higher than that of epoetin alfa groups. Non- significant changes were observed in potassium level and platelets count between the two groups. One case of Fistula thrombosis and local pain or tissue reaction to S.C injection was reported in methoxy polyethylene glycol epoetin beta arm. Other adverse events and complications include flu-like symptoms, diarrhea and blood transfusion was reported in both arms There were no hypertension and no death reported. Conclusion: methoxy polyethylene glycol-epoetin beta every two week effectively corrected chronic kidney disease (CKD) related anemia and was well tolerated and it is efficacy and safety is comparable to twice weekly epoetin alfa for anemia correcting in hemodialysis patients.

Keywords:
methoxy polyethylene glycol-epoetin beta end-stage renal disease anemia epoetin alfa

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Edgar V. Lerma, Jeffrey S. Berns, Allen R. Nissenson. Current Essentials of Nephrology & Hypertension McGraw-Hill Companies. United States 2012 June; chapter 3:113-123.
[2]	KDOQI National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47 [Suppl 3]: S11-S145.
[3]	World Health Organization. Worldwide Prevalence of Anaemia 1993-2005: WHO Global Database on Anaemia. In: de Benoist B, McLean E, Egli I and M Cogswell (eds), 2008.
[4]	Christina E. Lankhorst a, Jay B. Wish. Anemia in renal disease: Diagnosis and management. ELSEIVER. Blood Reviews. 2010; (24), 39-4.
[5]	Lasch KF, Evans CJ, Schatell D. A qualitative analysis of patient reported symptoms of anemia. Nephrol Nurs J 2009; 36: 621-622.
[6]	Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between Changes in hemoglobin and administered erythropoiesis stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17(4):1181-1191.
[7]	Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514-1521.
[8]	Gilbertson DT, Weinhand E, Ebben J, Collins AJ. An investigation of temporal relationship between hemoglobin levels and EPO doses J Am Soc Nephrol 2005; 16: 875A (abstract PUB430).
[9]	Modi GK, Zha V et al. The incidence of end-stage renal disease in India: A population-based study. Kidney Int 2006;70:2131-2133.
[10]	Macdougall IC: CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia Curr Hematol Rep 2005;4:436-440.
[11]	Committee for Medicinal Products for Human Use, European Medicines Agency. Scientific discussion. In: Mircera: European public assessment report. London: EMEA; 2007.
[12]	Francesco Locatelli,Lucia Del Vecchio. Erythropoiesis-Stimulating Agents in Renal Medicine The Oncologist .2011; 16(suppl 3): 19-24.
[13]	Macdougall IC, Walker R, Provenzano R, Alvaro FD, Locay HR, Nader PC et al. CERA Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial. Clin J Am Soc Nephrol 2008; 3: 337-347.
[14]	Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S et al. CERA Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. Am J Nephrol 2008;28:280–289.
[15]	Sameer G. Vankar, Pinaki Dutta, H.S. Kohli, et al. Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis. Indian J Med Res .January 2014; pp 112-116.
[16]	Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2(4): 279-335.
[17]	Francesco Locatelli, Salvatore Mandolfo, Massimo Menegato Adorati,etal. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia. JNEPHROL .2013; 26(6): 1114-1121.
[18]	Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007; 50(6): 989-1000.
[19]	Hassan Argani, Shahrzad Ossareh, Samira Tabiban,et al. PDpoietin in comparison with Eprex in treatment of anemic patients on hemodialysis. IJKD. 2009; 3: 145-50.
[20]	England JM, Rowan RM, Bins M, et al. Recommended methods for the determination of packed cell volume by centrifugation: The Expert Panel on Cytometry of the International Committee for Standardization in Haematology. WHO/LAB; 1989:1.
[21]	HK Aggarwal, R Sehgal, S Singh,etal. Evaluation of efficacy of low dose recombinant human erythropoietin in combination with androgen therapy in anaemia of chronic renal failure. JIACM. 2005; 6(3): 208-15.
[22]	Lawrence T. Goodnough, Barry Skikne, and Carlo Brugnara. Erythropoietin, iron, and erythropoiesis. BLOOD, Augest 2000; 96(3).
[23]	Valentina Forni, Giorgia Bianchi, Adam Ogna,etal. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology .2013; 14:157.
[24]	TOSHIAKI TAKAHASHI, NOBUYUKI YAMAMOTO, TOMOHIDE TAMURA, et al. Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. ONCOLOGY LETTERS 2: 1033-1040, 2011.
[25]	Hsieh M., Wu I., Lee C., Wang S., Wu M. (2011). Higher serum potassium level associated with late stage chronic kidney disease.
[26]	Owiredu W., Ephraim R., Amidu B. and Laing E. (2012). Relationship between parathyroid hormone and electrolytes in chronic kidney disease. Journal of Medical Research 1(8):0103-0111.
[27]	A.laupacis, Quality of life and exercise capacity in anaemic hemodialysis patients treated with erythropoietin. NEFROLOGIA. 1990; VOL X, supplement 3.
[28]	Luc Frimat, Christophe Mariat, Paul Landais,et al. Anaemia management with C.E.R.A. in routine clinical practice: (CohorteMircera patients non-dialysés), OCEANE a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 2013; 3.
[29]	Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-9.